VCYT
Veracyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.53
−4.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 561.9M | 517.1M | 445.8M | 361.1M | 296.5M |
| Cost of Revenue | 156.8M | 157.1M | 147.6M | 112.9M | 101.6M |
| Gross Profit | 405.1M | 360.0M | 298.1M | 248.1M | 195.0M |
| Operating Expenses | |||||
| R&D Expense | 93.4M | 70.8M | 69.3M | 57.3M | 40.6M |
| SG&A Expense | 201.6M | 210.9M | 206.0M | 184.2M | 174.1M |
| General & Admin Expense | 95.8M | 110.8M | 178.3M | 157.6M | 76.5M |
| Selling & Marketing Expense | 105.8M | 100.2M | 27.8M | 26.6M | 97.6M |
| Other Expenses | 14.4M | 4.1M | 6.7M | 92.4M | 21.4M |
| Total Operating Expenses | 309.4M | 285.9M | 282.0M | 333.9M | 236.0M |
| Cost and Expenses | 466.2M | 443.0M | 429.6M | 446.8M | 337.6M |
| Operating Income (EBIT) | 95.7M | 74.2M | 16.1M | (85.8M) | (41.1M) |
| Non-Operating | |||||
| Interest Income | 14.4M | — | 11.2M | 7.3M | 2.0M |
| Interest Expense | — | — | 2.0K | 15.0K | 198.0K |
| Net Interest Income | 14.4M | — | 11.2M | 7.3M | 1.8M |
| Other Non-Op Income/Expense | 13.2M | (5.9M) | 9.6M | 9.2M | 4.7M |
| Non-Operating Income (excl Interest) | (13.2M) | 5.9M | (9.6M) | (9.2M) | (4.9M) |
| EBT (Pre-Tax Income) | 108.9M | 68.2M | 25.7M | (76.6M) | (36.4M) |
| Income Tax Expense | (5.5M) | 1.8M | 1.6M | (2.2M) | 133.0K |
| Bottom Line | |||||
| Net Income | 114.5M | 66.4M | 24.1M | (74.4M) | (36.6M) |
| Earnings from Cont. Ops | 114.5M | 66.4M | 24.1M | (74.4M) | (36.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 114.5M | 66.4M | 24.1M | (74.4M) | (36.6M) |
| Per Share | |||||
| Basic EPS | $1.44 | $0.84 | $0.32 | ($1.02) | ($0.51) |
| Diluted EPS | $1.40 | $0.82 | $0.31 | ($1.02) | ($0.51) |
| Revenue Per Share | $7.05 | $6.58 | $5.83 | $4.97 | $4.14 |
| Shares | |||||
| Basic Shares Outstanding | 79.7M | 78.6M | 76.5M | 72.6M | 71.5M |
| Diluted Shares Outstanding | 82.2M | 80.6M | 78.2M | 72.6M | 71.5M |
| Profitability Metrics | |||||
| EBITDA | 129.8M | 89.6M | 49.2M | (49.4M) | (7.0M) |
| D&A | 20.8M | 21.4M | 23.5M | 27.2M | 29.2M |
| EBIT | 108.9M | 68.2M | 25.7M | (76.6M) | (36.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026